Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Exploring Novel Treatment Strategies for Metastatic Colorectal Cancer

Access Activity

Overview / Abstract:


Colorectal cancer (CRC) is the third leading cause of cancer death among men and women in the United States. An estimated 145,600 new cases are diagnosed annually and 51,020 people die of the disease. When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because CRC initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages. Approximately 21% of patients present with metastatic disease, which is associated with a 5-year survival rate of only 14%.


Medical oncologists, gastroenterologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with CRC.


Upon completion of this activity, participants should be able to:

1.) Distinguish predictive and prognostic markers that can refine individualized treatment of metastatic CRC
2.) Apply current and emerging data on novel therapies in clinical management of metastatic CRC
3.) Appraise recent data on novel combination and sequential treatment strategies for patients with metastatic CRC


Jun 04, 2021


Nurse Practitioner , Physician CME, Physician Assistant CME

Credits / Hours

1.25 CME, 1.25 MOC



Presenters / Authors / Faculty

Jaffer A. Ajani, MD
Professor of Medicine
MD Anderson Cancer Center

Activity Specialities / Related Topics

Gastroenterology / GI, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Amgen.

Keywords / Search Terms

i3 Health i3 Health, colorectal cancer, CRC, CME, free CE CME, free CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map